海峽創新(300300.SZ):將喪失對好醫友的控制權並不再將其納入公司合併報表範圍
格隆匯 11 月 27日丨海峽創新(300300.SZ)公佈,2018年5月,漢鼎宇佑集團有限公司(“宇佑集團”)與海峽創新互聯網股份有限公司(曾用名:漢鼎宇佑互聯網股份有限公司,“公司”)簽訂了《表決權委託協議》(“原協議”),協議約定宇佑集團將其所持有的好醫友醫療科技集團有限公司(曾用名:好醫友醫療科技有限公司,“好醫友”)10%股權對應的全部表決權委託給公司行使,公司接受委託後合計持有好醫友50%股權對應的表決權,並且在好醫友公司章程規定的董事會3個席位中佔有2席,獲得好醫友實際控制權,好醫友成為公司控股子公司。
鑑於宇佑集團本身戰略規劃需要,經過協商,近日宇佑集團與公司簽訂《解除協議》,雙方約定:“原協議自本協議簽訂後立即解除,雙方於原協議項下的權利義務立即終止。”
根據《公司章程》的有關規定,此次交易事項無需提交董事會審議,亦不構成《上市公司重大資產重組管理辦法》規定的重大資產重組情況。
在宇佑集團解除表決權委託後,公司可實際控制的好醫友股權比例為40%,可委派到好醫友董事人數為一名。基於上述情況,在宇佑集團解除委託後,公司持有好醫友的持股比例不足50%,無法獨立行使在好醫友股東會和董事會中的超半數表決權,公司將喪失對好醫友的控制權並不再將好醫友納入公司合併報表範圍。
鑑於好醫友資產規模、營業收入及利潤指標占公司的比重較低,不再納入公司合併報表範圍後對公司財務指標影響較小。關於該事項對公司財務報表具體影響以公司年度會計師的審計結果為準。
未來,公司將以與好醫友共同參股公司好醫友(平潭)互聯網醫院為智慧醫療的主要實施平台,同時導入好醫友豐富的海外醫療資源、先進的跨境醫療服務、成熟的業務體系等渠道和資源,加大與互聯網醫院業務的資源整合,不斷深化中外醫療業務合作;突出互聯網醫院在智慧醫療板塊中的核心地位,加強智慧醫療業務的服務深度和廣度,充分利用福建省平潭綜合實驗區的區位和政策優勢,實現智慧醫療戰略優化和業務的升級迭代。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.